Cureus · 2025
Effectiveness of Goreisan in Ménière's Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koda Yuki
Аннотация
OBJECTIVE: This study evaluates the effectiveness of Goreisan, a traditional Kampo medicine, in treating Ménière's disease (MD), focusing on vertigo frequency, dizziness severity, and hearing function.
METHODS: A retrospective analysis was conducted on 164 patients diagnosed with definite MD between April 2017 and March 2022. Among them, 52 patients received Goreisan treatment, while 31 patients did not receive any diuretic therapy. Vertigo frequency, Dizziness Handicap Inventory (DHI) scores, and hearing function were assessed over a 12-month period.
RESULTS: Patients in the Goreisan group showed a significant reduction in vertigo frequency at two, six, and 12 months, whereas the no-medication group showed significant improvement only at two months. DHI scores improved in both groups, suggesting that betahistine and lifestyle modifications may contribute to symptom relief. No significant changes in hearing function were observed in the Goreisan group.
CONCLUSION: Goreisan may be an effective and safe treatment option for reducing vertigo frequency in MD patients. However, it does not appear to improve hearing function. Further placebo-controlled studies are needed to confirm its efficacy.
METHODS: A retrospective analysis was conducted on 164 patients diagnosed with definite MD between April 2017 and March 2022. Among them, 52 patients received Goreisan treatment, while 31 patients did not receive any diuretic therapy. Vertigo frequency, Dizziness Handicap Inventory (DHI) scores, and hearing function were assessed over a 12-month period.
RESULTS: Patients in the Goreisan group showed a significant reduction in vertigo frequency at two, six, and 12 months, whereas the no-medication group showed significant improvement only at two months. DHI scores improved in both groups, suggesting that betahistine and lifestyle modifications may contribute to symptom relief. No significant changes in hearing function were observed in the Goreisan group.
CONCLUSION: Goreisan may be an effective and safe treatment option for reducing vertigo frequency in MD patients. However, it does not appear to improve hearing function. Further placebo-controlled studies are needed to confirm its efficacy.